These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7747708)

  • 21. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
    Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
    Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Medical treatment of metastatic cancer of the kidney with a combination of vinblastine and recombinant interferon alpha IIa. Result of a phase I-II trial].
    Jacqmin D; Bergerat JP; Dufour P; Bollack C; Prévot G; Jurascheck F; Bailly G; Degaris S; Oberling F
    J Urol (Paris); 1987; 93(8):463-6. PubMed ID: 3440838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
    Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
    J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot study of low dose hydroxyurea as a novel resistance modulator in metastatic renal cell cancer.
    Hao D; Huan SD; Stewart DJ; Segal RJ; Yau JC
    J Chemother; 2000 Aug; 12(4):360-6. PubMed ID: 10949987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study.
    Bukowski RM; Goodman P; Crawford ED; Sergi JS; Redman BG; Whitehead RP
    J Natl Cancer Inst; 1990 Jan; 82(2):143-6. PubMed ID: 2294224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma.
    Sertoli MR; Brunetti I; Ardizzoni A; Falcone A; Guarneri D; Boccardo F; Martorana G; Curotto A; Sicignano A; Rosso R
    Am J Clin Oncol; 1989 Feb; 12(1):43-5. PubMed ID: 2492141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study.
    Liu JH; Yang MH; Fan FS; Yen CC; Wang WS; Chang YH; Chen KK; Chen PM
    Urology; 2001 Apr; 57(4):650-4. PubMed ID: 11306370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.
    Mickisch GH; Noordzij MA; vd Gaast A; Gebreamlack P; Köhrmann KU; Mogler-Drautz E; Kupper H; Schröder FH
    J Cancer Res Clin Oncol; 1995; 121 Suppl 3():R11-6. PubMed ID: 8698736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon-alpha-n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma.
    Trump DL; Ravdin PM; Borden EC; Magers CF; Whisnant JK
    J Biol Response Mod; 1990 Feb; 9(1):108-11. PubMed ID: 2319258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma.
    Einhorn LH; Roth BJ; Ansari R; Dreicer R; Gonin R; Loehrer PJ
    J Clin Oncol; 1994 Nov; 12(11):2271-6. PubMed ID: 7525884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
    Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
    J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials.
    Bacoyiannis C; Dimopoulos MA; Kalofonos HP; Nicolaides C; Aravantinos G; Bafaloukos D; Samelis G; Onyenadum A; Kiamouris Ch; Skarlos D; Pavlidis N; Triantafillidis A; Kosmidis P;
    Oncology; 2002; 63(2):130-8. PubMed ID: 12239447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Further experience with recombinant interferon alfa-2a with vinblastine in metastatic renal cell carcinoma: a progress report.
    Fosså SD; De Garis ST
    Int J Cancer Suppl; 1987; 1():36-40. PubMed ID: 3476476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
    Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
    Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
    Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
    Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant interferon-alpha 2a and vinblastine in advanced renal cell cancer: a clinical phase I-II study.
    Kellokumpu-Lehtinen P; Nordman E
    J Biol Response Mod; 1990 Aug; 9(4):439-44. PubMed ID: 2395008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of misonidazole (MISO) and cyclophosphamide (CYC) in metastatic renal cell carcinoma.
    Glover D; Trump D; Kvols L; Elson P; Vogl S
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1405-8. PubMed ID: 3759565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does vinblastine add to the potency of alpha interferon in the treatment of renal cell carcinoma?
    Merimsky O; Shnider BI; Chaitchik S
    Mol Biother; 1991 Mar; 3(1):34-7. PubMed ID: 2069758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells.
    Kuebler JP; Whitehead RP; Ward DL; Hemstreet GP; Bradley EC
    J Urol; 1993 Sep; 150(3):814-20. PubMed ID: 8345590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
    Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
    J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.